A. Johnson‐Levonas

发表

Lipid‐altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials

Lawrence A Leiter, J. Guyton, P. Brudi, 2011, Diabetes, obesity & metabolism.

Efficacy and safety of ezetimibe co‐administered with ongoing atorvastatin therapy in achieving low‐density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease

J. Adgey, A. Johnson‐Levonas, J. M. Cruz-Fernández, 2005, International journal of clinical practice.

Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans.

D. Connolly, J. Paolini, J. Wagner, 2008, Journal of clinical lipidology.

Lipid‐altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high‐risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – The IN‐CROSS study

M. Viigimaa, L. Missault, P. Brudi, 2009, International journal of clinical practice.

Effects of Rifampin, a Potent Inducer of Drug‐Metabolizing Enzymes and an Inhibitor of OATP1B1/3 Transport, on the Single Dose Pharmacokinetics of Anacetrapib

Yang Liu, D. Gutstein, J. Cote, 2013, Journal of clinical pharmacology.

Influence of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin

Fang Liu, J. Wagner, K. Lasseter, 2009, American journal of therapeutics.

Multiple Doses of Sitagliptin, a Selective DPP‐4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin

G. Herman, J. Wagner, A. Johnson‐Levonas, 2009, Journal of clinical pharmacology.

Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin

J. Wagner, K. Lasseter, J. Schwartz, 2008, Advances in therapy.

A Dual PPAR α/γ Agonist Increases Adiponectin and Improves Plasma Lipid Profiles in Healthy Subjects

Haiyuan Zhu, K. Decochez, B. Keymeulen, 2006 .

Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.

C. Roehrborn, P. Narayan, B. Saltzman, 2002, European urology.

Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.

M. Viigimaa, L. Missault, P. Brudi, 2011, Clinical biochemistry.

Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.

D. Tribble, T. Musliner, L. Ose, 2007, Clinical therapeutics.

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.

Y. Shentu, B. Goldstein, V. Fonseca, 2013, Journal of diabetes and its complications.

Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.

B. Gumbiner, L. Masana, Meehyung Cho, 2005, Clinical therapeutics.

Family History and Risk of Hair Loss

Shumei S. Guo, C. Girman, W. Chumlea, 2004, Dermatology.

Prevalence of microalbuminuria and associated risk factors among adult Korean hypertensive patients in a primary care setting

B. Oh, Y. Kim, Moon-Kyu Lee, 2013, Hypertension Research.

Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity

M. Viigimaa, L. Missault, P. Brudi, 2011 .

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome

M. Viigimaa, L. Missault, P. Brudi, 2011, Diabetes & vascular disease research.

Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone

S. Kaplan, A. Johnson‐Levonas, Jianxin Lin, 2010, The aging male : the official journal of the International Society for the Study of the Aging Male.

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

H. Bays, A. Maclean, E. Brinton, 2015, Vascular health and risk management.

Extended-Release Niacin/Laropiprant Significantly Improves Lipid Levels in Type 2 Diabetes Patients Irrespective of Baseline Glycemic Control

H. Bays, A. Maclean, E. Brinton, 2012 .

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

D. Tatosian, J. Wagner, R. Krishna, 2016, Journal of clinical pharmacology.

Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event

D. Henry, P. Brudi, T. Pomykaj, 2008, Cardiology.

Pharmacokinetics of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment

J. Wagner, K. Lasseter, T. Marbury, 2011, Journal of clinical pharmacology.

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

P. Brudi, M. Farnier, Q. Dong, 2011, Lipids in Health and Disease.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

D. Cutler, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.

D. Tatosian, C. Matthews, Diana Selverian, 2016, Clinical therapeutics.

Effects of Once-daily Sitagliptin on 24-h Glucose Control Following 4 Weeks of Treatment in Japanese Patients with Type 2 Diabetes Mellitus

J. Amatruda, A. Johnson‐Levonas, K. Nonaka, 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single‐ and Multiple‐Dose Pharmacokinetics of Vorapaxar

D. Cutler, T. Kosoglou, P. Statkevich, 2013, Journal of clinical pharmacology.

The Influence of Multiple‐Dose Vorapaxar, an Oral PAR‐1 Receptor Antagonist, on the Single‐Dose Pharmacokinetics and Pharmacodynamics of Digoxin

D. Cutler, T. Kosoglou, P. Statkevich, 2013, Clinical pharmacology in drug development.

The minimal impact of food on the pharmacokinetics of ridaforolimus

J. Wagner, M. Trucksis, D. Panebianco, 2012, Cancer Chemotherapy and Pharmacology.

Elevated high sensitivity C-reactive protein levels in aging men with low testosterone

S. Kaplan, A. Johnson‐Levonas, Jianxin Lin, 2010, The aging male : the official journal of the International Society for the Study of the Aging Male.

Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.

S. Miller, D. Cutler, T. Kosoglou, 2013, Chest.

Long‐term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2‐year, open‐label extension study

D. Lütjohann, K. von Bergmann, T. Musliner, 2008, International journal of clinical practice.

Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss.

S. Heymsfield, D. Thompson, A. Strack, 2012, Metabolism: clinical and experimental.

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

D. Rader, S. Previs, B. Hubbard, 2017, Arteriosclerosis, thrombosis, and vascular biology.

Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid‐1 Receptor (CB1R) Inverse Agonist

J. Chodakewitz, J. Wagner, P. Jumes, 2009, Journal of clinical pharmacology.

Influence of Taranabant, an Orally Active, Highly Selective, Potent Cannabinoid‐1 Receptor (CB1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Plasma Pharmacokinetics

J. Wagner, K. Lasseter, J. Schwartz, 2009, Journal of clinical pharmacology.

A TWO-YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF TARANABANT IN OBESE PATIENTS: 52 WEEK RESULTS

S. Heymsfield, I. Gantz, S. Suryawanshi, 2008 .

A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once‐Weekly DPP‐4 Inhibitor, Does Not Prolong the QTc Interval

D. Tatosian, E. Kauh, A. Johnson‐Levonas, 2016, Clinical pharmacology in drug development.

Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.

J. Paolini, A. Bergman, B. Yi, 2006, International journal of clinical pharmacology and therapeutics.

Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo.

A. Rodgers, E. Round, K. Kaufman, 2012, Journal of the American Academy of Dermatology.

Ezetimibe

J. Paolini, A. Bergman, K. Alton, 2005, Clinical pharmacokinetics.

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).

M. Minden, H. Kantarjian, F. Ravandi, 2015, Leukemia research.

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.

H. Daida, H. Arai, T. Teramoto, 2016, Atherosclerosis.

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.

D. Hong, U. Banerji, N. Somaiah, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Lovastatin Therapy in Adolescent Girls With Heterozygous Familial Hypercholesterolemia

P. Hopkins, K. Holmes, E. Stein, 2005, Pediatrics.

An enhanced bunionectomy model as a potential tool for early decision-making in the development of new analgesics

C. Beals, L. Webster, G. Herman, 2010, Advances in therapy.

A PK-PD model-based assessment of sugammadex effects on coagulation parameters.

S. Visser, M. V. van Lierop, P. De Kam, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.

C. Matthews, J. Wagner, K. Gottesdiener, 2010, Clinical drug investigation.

Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects

C. Matthews, J. Wagner, K. Gottesdiener, 2010, Clinical drug investigation.

Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects

A. Bergman, J. Wagner, K. Lasseter, 2011, Journal of clinical pharmacology.

The Effects of Multiple Doses of Rolofylline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Subjects

H. Dittrich, J. Wagner, M. Stroh, 2010, American journal of therapeutics.

A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans

C. Beals, R. Carey, M. Malice, 2012, Journal of hypertension.

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

J. Kastelein, J. Bergeron, G. Hovingh, 2015, The Lancet.

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.

W. Sheu, C. Ballantyne, D. Kang, 2017, The American journal of cardiology.

A multi‐centre, randomised, double‐blind 14‐week extension study examining the long‐term safety and efficacy profile of the ezetimibe/simvastatin combination tablet *

D. Tribble, T. Musliner, J. Lin, 2007, International journal of clinical practice.

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

A. Maclean, P. Brudi, E. Brinton, 2016, Lipids in Health and Disease.

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia

M. Farnier, A. Johnson‐Levonas, E. Chen, 2014, Vascular health and risk management.

Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.

J. Guyton, P. Brudi, M. Farnier, 2013, Atherosclerosis.

Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.

C. Ballantyne, G. Gleim, Nancy Liu, 2012, Journal of clinical lipidology.

Effect of Laropiprant, a PGD2 Receptor 1 Antagonist, on Estradiol and Norgestimate Pharmacokinetics After Oral Contraceptive Administration in Women

J. Wagner, M. Gutierrez, J. Schwartz, 2009, American journal of therapeutics.

The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

B. Goldstein, K. Kaufman, D. Williams-Herman, 2011, Diabetes, obesity and metabolism.

Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes

Lawrence A Leiter, J. Guyton, P. Brudi, 2011, Diabetes & vascular disease research.

Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus *

N. Chung, A. Johnson‐Levonas, C. Allen, 2007, Diabetes, obesity & metabolism.

Lipid‐altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease

V. Barrios, N. Amabile, A. Johnson‐Levonas, 2005, International journal of clinical practice.

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.

D. Tribble, H. Bays, Neil J. Fraser, 2004, Clinical therapeutics.

Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism

J. Elbers, P. Bouloux, E. Meuleman, 2015, The aging male : the official journal of the International Society for the Study of the Aging Male.

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes *†

Y. Shentu, Wenying Yang, S. Engel, 2012, Journal of diabetes.

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib[S]

R. Krauss, C. Pinto, J. Wagner, 2012, Journal of Lipid Research.

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.

M. Viigimaa, L. Missault, P. Brudi, 2012, Cardiovascular therapeutics.

A Single Supratherapeutic Dose of Rolofylline Does Not Prolong the QTcF Interval in Healthy Volunteers

J. Wagner, M. Stroh, A. Johnson‐Levonas, 2010, American journal of therapeutics.

Assessment of pharmacokinetic interactions between ezetimibe and cyclosporine

J. Paolini, A. Bergman, T. Kosoglou, 2005 .

Lipid‐altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study

P. Henry, J. Reckless, P. Brudi, 2008, International journal of clinical practice.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, The Journal of clinical investigation.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2015, The Journal of clinical investigation.

Abstract 683: Lipid-Altering Efficacy and Safety Profile of Co-administered Extended Release Niacin/Laropiprant and Simvastatin in Patients with Dyslipidemia

C. Ballantyne, R. Pasternak, J. Paolini, 2007 .

Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome.

D. Tribble, L. Ose, E. Veltri, 2007, Metabolic syndrome and related disorders.

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.

R. Krauss, C. Pinto, Yang Liu, 2015, Journal of clinical lipidology.

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

A. Rissanen, S. Heymsfield, J. Proietto, 2010, International Journal of Obesity.

Addressing a Treatment Gap

J. Isaacsohn, P. Landsman, A. Johnson‐Levonas, 2002 .

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

J. Paolini, W. Kraft, H. Greenberg, 2006, Journal of clinical pharmacology.

A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

K. Fujioka, Y. Shentu, S. Heymsfield, 2010, Diabetes, obesity & metabolism.

Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.

H. Daida, H. Arai, T. Teramoto, 2017, Atherosclerosis.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

D. Cutler, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.

C. Ballantyne, A. Johnson‐Levonas, Y. Mitchel, 2017, The American journal of cardiology.

A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low‐Calorie Diet

S. Toubro, K. Fujioka, T. Wadden, 2010, Obesity.

Interaction of Single‐Dose Ezetimibe and Steady‐State Cyclosporine in Renal Transplant Patients

J. Paolini, A. Bergman, R. Robson, 2006, Journal of clinical pharmacology.

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

A. Maclean, P. Brudi, E. Brinton, 2016, Lipids in Health and Disease.

The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

W. Kraft, J. Wagner, A. van Hecken, 2011, Platelets.

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

J. Wagner, D. Ebel, G. Atiee, 2010, Journal of clinical pharmacology.

Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Steady‐State Pharmacokinetics of Digoxin in Healthy Adult Subjects

J. Wagner, A. Johnson‐Levonas, L. Wenning, 2010, Journal of clinical pharmacology.

Jefferson Digital

Inge, W. Kraft, J. Wagner, 2022 .

Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers

J. Wagner, Yang Liu, A. Johnson‐Levonas, 2014, Journal of clinical pharmacology.

Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20mg Compared with Rosuvastatin 10mg in High-Risk Patients with and Without Type 2 Diabetes Mellitus (T2DM)

M. Viigimaa, L. Missault, P. Brudi, 2009 .